Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 
Open AccessResearch

HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor

Tomohide Tsukahara1,2 email, Satoshi Kawaguchi1 email, Toshihiko Torigoe2 email, Akari Takahashi2 email, Masaki Murase1,2 email, Masanobu Kano1,2 email, Takuro Wada1 email, Mitsunori Kaya1 email, Satoshi Nagoya1 email, Toshihiko Yamashita1 email and Noriyuki Sato2 email

Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060-8543, Japan

Department of Pathology, Sapporo Medical University School of Medicine, South-1, West-17, Chuo-ku, Sapporo, 060-8556, Japan

author email corresponding author email

Journal of Translational Medicine 2009, 7:44doi:10.1186/1479-5876-7-44

Published: 12 June 2009

Additional files

Additional file 1:

Sequences and binding affinities of PBF-derived peptides with HLA-A*0201 binding motif. *Binding score was determined by BIMAS HLA Peptide Binding Predictions. The affinity of each peptide (50 μg/ml) was evaluated by a HLA class I stabilization assay.

Format: XLS Size: 17KB Download file

This file can be viewed with: Microsoft Excel Viewer

Open Data

Additional file 2:

Clinical picture and frequency of anti-PBF A2.2 peptide CTLs in PBMC of patients with osteosarcoma. P: primary tumor, M: metastatic tumor. Frequency of anti-PBF A2.2 CTLs among CD8+ cells. Parentheses indicate that the tumor had been resected at the time of blood sampling. §Magnetically separated CD8+ cells. Irradiated peptide-pulsed CD8- cells were used as stimulator.

Format: XLS Size: 37KB Download file

This file can be viewed with: Microsoft Excel Viewer

Open Data

© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.